BioMarin Pharmaceutical Inc.
BMRNNASDAQ
Healthcare
Biotechnology
$55.51
-1.74(-3.0%)
52W $51.46 – $64.08
AI-generated
BioMarin Pharmaceutical Inc.
Revenue breakdown: Products Excluding ALDURAZYME (47.4%), Product (25.3%), VIMIZIM (6.8%).
$10.7BMkt Cap
$3.2BRev TTM
$350MNI TTM
30.1xP/E TTM
Latest Earnings
10-K
FY FY2025Feb 25, 202610-K for FY2025 was filed on 2026-02-26. AI summary is not available yet.
What Changed Recently
Fundamentals
How The Business Makes Money
Revenue by Segment
Products Excluding ALDURAZYME47.4%($15.7B)
Product25.3%($8.3B)
VIMIZIM6.8%($2.2B)
VOXZOGO6.5%($2.1B)
NAGLAZYME4.2%($1.4B)
PALYNZIQ3.3%($1.1B)
ALDURAZYME3.2%($1.0B)
BRINEURA1.6%($517M)
KUVAN1.2%($401M)
Royalty And Other0.4%($145M)
ROCTAVIAN0.2%($65M)
Revenue by Geography
US35.8%($2.8B)
Europe30.3%($2.4B)
Rest Of World19.2%($1.5B)
Latin America14.6%($1.1B)
Analyst View
Company Profile
CIK0001048477
ISINUS09061G1013
CUSIP09061G101
Phone415 506 6700
Address770 Lindaro Street, San Rafael, CA, 94901, US
SEC EDGAR